GMAB News and Press, Genmab A/S From 08/12/20

Image source: The Motley Fool. Genmab A/S   (NASDAQ: GMAB) Q2 2020 Earnings Call Aug 12, 2020 , 12:00 p.m. ET Operator Continue reading

Genmab (NASDAQ: GMAB ) : Q2 GAAP EPS of DKK51.35. Revenue of DKK5.45B (+604.2% Y/Y). Press Release More news on: Genmab A/S, Genmab A/S, Earnings news and commentary, Tech stocks news,

Danish biotech Genmab ( GMAB +0.6% ) reports H1 results . Highlights: More news on: Genmab A/S, Healthcare stocks news, Earnings news and commentary, , Read more ...

Health Canada has approved a subcutaneous formulation of Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceutical Companies' multiple myeloma med Darzalex (daratumumab), originally approved for intravenous administration. More news on: Johnson & Johnson, Genmab A/S, Halozyme ...

According to data published by the U.S. Social Security Administration (SSA) in December 2019, the median monthly benefit paid out to retired individuals is just $1,503. For disabled individuals, the average monthly benefit was just $1,258. The SSA estimates that approximately nine out of 10 per...

Genmab A/S (NASDAQ: GMAB ) announces positive results from an open-label Phase 3 clinical trial, APOLLO , evaluating a subcutaneous formulation of licensor Janssen Biotech's [a unit of Johnson & Johnson (NYSE: JNJ ) ] Darzalex (daratumumab), combined with pomalidomide and dexametha...

Thesis Summary AbbVie Inc. ( ABBV ) seems, on the surface, like an incredibly undervalued stock offering a 4.75% dividend yield with a payout ratio of under 50%. Upon further inspection though, it becomes clear that due to is dependence on HUMIRA, its best days may be behind it. Still, consi...

The FDA has placed a partial clinical hold on a pivotal Phase 2 clinical trial evaluating ADC Therapeutics' (NYSE: ADCT ) antibody-drug conjugate camidanlumab tesirine in patients with relapsed/refractory Hodgkin lymphoma. More news on: ADC Therapeutics SA, Genmab A/S, Healthcare stock...

Over the past several months, the coronavirus stock market has proven nerve-wracking for even the most seasoned of investors. We are living in unprecedented times. But the basic rules of investing haven't changed, and there are still worthwhile investment opportunities to be found. Eli Lilly...

Seattle Genetics (NASDAQ: SGEN ) and collaboration partner Genmab A/S (NASDAQ: GMAB ) announce positive topline results from a Phase 2 clinical trial, innovaTV 204 , evaluating antibody-drug conjugate (ADC) tisotumab vedotin in patients with relapsed/refractory metastatic cervical cancer....